Many physician organizations have looked into screening for ovarian cancer. Currently, they recommend that only women who are at high risk-those who have a genetic mutation or a strong family history of breast and/ or ovarian cancer-should undergo routine screening. Screening includes regular CA-...
Epithelial ovarian cancer (EOC) is a deadly disease with limited diagnostic biomarkers and therapeutic targets. Here we conduct a comprehensive proteomic profiling of ovarian tissue and plasma samples from 813 patients with different histotypes and thera
Expert commentary: In ovarian cancer, considerable discord exists between patients and physicians regarding perceived symptom burden. During maintenance therapy, it is important that the most appropriate PROs (i.e. endpoints and respective measuring tools) are selected to evaluate patients. Research ...
Ovarian cancer is one of the most common cancers in women and is often diagnosed as advanced stage because of the subtle symptoms of early ovarian cancer. To identify the somatic alterations and new biomarkers for the diagnosis and targeted therapy of Chinese ovarian cancer patients, a total of ...
We found ~300 proteoforms differentially detected in tumor versus stromal regions from ovarian cancer sections, where the patient can serve as their own control depending on the profiled regions in the experiment. This platform fills the gap between high-confidence proteoform discovery and spatial ...
Adjunctive medications include the following: Cytoprotective agents (eg, mesna) Antiemetics (eg, ondansetron, granisetron, palonosetron, dexamethasone) SeeTreatmentandMedicationfor more detail. For patient education information, see theOvarian Cancer Health Center....
摘要: Author information: (1)Division of Gynecologic Oncology, University of British Columbia, Vancouver, Canada. mark.carey@vch.ca关键词: Keywords Patient-reported outcomes Ovarian cancer Clinical trials DOI: 10.1097/IGC.0b013e31821bb8be 被引量: 5 ...
However, the true impact of these drugs on patient outcomes remains to be seen. This survey has a number of limitations. Although this survey was distributed to a wide array of oncologists, this may not be a representative sample of ovarian cancer treating physicians as information about non...
There has been some concern about the possible increased risk of ovarian cancer after treatment with medications that stimulate ovulation from the ovaries. Most well-designed studies show no increase in risk, while others have shown a slight increased risk in ovarian cancer after fertility treatment....
cancer therapy-related AML had received previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy. For suspected MDS/AML or prolonged hematological toxicities, refer the patient to a hematologist for further evaluation. Discontinue ZEJULA if MDS/AML is confirmed....